International AIDS Vaccine Initiative (IAVI) and Merck & Co. scientists have developed a SARS-CoV-2 vaccine using the vesicular stomatitis virus (VSV) chimeric virus approach, wherein VSV was modified by substituting the VSV G surface glycoprotein gene with a coding sequence for the SARS-CoV-2 spike (S) glycoprotein.